Blockbuster weight loss and diabetes medications may be on the verge of another significant breakthrough. Four new studies suggest a connection between GLP-1 drugs, such as Novo Nordisk A/S's Ozempic and Eli Lilly's Mounjaro, and improved outcomes for cancer patients. This finding could further expand the market potential for these drugs, already used by tens of millions, and provide new growth drivers for these two of the world's most valuable pharmaceutical companies. The studies, set to be presented later this month at the American Society of Clinical Oncology (ASCO) annual meeting, involve data from over hundreds of thousands of patients. The largest among them, from the Cleveland Clinic Cancer Institute, tracked more than 10,000 patients with early-stage cancer. It found that GLP-1 drug users had a significantly lower risk of cancer progression compared to a control group—the rate of disease progression was roughly halved for lung cancer patients, and similarly decreased from 20% to 10% for breast cancer patients. Another study indicated a five-year survival rate exceeding 95% for breast cancer patients using GLP-1 drugs, compared to 89.5% for non-users. If the anti-cancer benefits are ultimately confirmed, it would further solidify the market positions of Novo Nordisk A/S and Eli Lilly. GLP-1 drugs are already approved for reducing the risk of heart attack and stroke, and are being tested for efficacy against sleep apnea and addictive behaviors. Anti-cancer benefits would once again expand the medical value frontier of these drugs and could reshape their pricing and reimbursement logic. However, researchers clearly stated that the current evidence shows correlation, not causation. All four studies are retrospective observational analyses relying on insurance claims records and medical databases. Confirmation through randomized controlled trials is still needed. Currently, neither Novo Nordisk A/S nor Eli Lilly has initiated dedicated clinical studies targeting the anti-cancer effects of GLP-1 drugs.
Significant Decline in Progression Rates Across Multiple Cancers, Consistent Data Signals
The Cleveland Clinic Cancer Institute study compared over 10,000 patients who started using GLP-1 drugs after an early-stage cancer diagnosis with patients using other diabetes medications. The results showed GLP-1 users had a lower risk of cancer spread. The specific data is quite striking: among lung cancer patients, the proportion progressing to advanced stages was about 10% in the GLP-1 group versus 22% in the control group, a reduction of approximately 50%. For breast cancer patients, progression rates were 10% and 20%, respectively. Statistically significant declines were also observed for colorectal and liver cancers. "Given that millions of Americans are using GLP-1 drugs, there is a clear and urgent need to understand their potential anti-tumor effects," said Dr. Mark Orland, a resident at the Cleveland Clinic who will present the study at the ASCO meeting. Dr. Jennifer Ligibel, a breast oncologist at Dana-Farber Cancer Institute who was not involved in any of the related studies, noted, "The finding that people using these drugs appear to have a lower risk of cancer recurrence across multiple cancer types is indeed remarkable."
Breast Cancer Data: Improvements in Both Incidence and Survival Rates
Two other studies specifically focused on breast cancer, examining the potential role of GLP-1 drugs from the perspectives of both incidence and survival. An analysis of over 137,000 breast cancer patients by the University of Texas MD Anderson Cancer Center showed a five-year survival rate exceeding 95% for GLP-1 users, compared to 89.5% for non-users. A study from the University of Pennsylvania involving nearly 95,000 women who underwent breast imaging found that those with a history of GLP-1 drug use had approximately a 25% lower risk of being diagnosed with breast cancer. This difference remained significant after controlling for age, weight, and other risk factors. Dr. Jasmine Sukumar, a breast oncologist at MD Anderson and a contributor to the survival rate study, stated, "We are seeing signals across multiple databases, which is certainly noteworthy given the different designs of these studies."
Debate Over Mechanism: Metabolic Improvement or Direct Tumor Targeting?
The scientific community currently has no consensus on why GLP-1 drugs might produce anti-cancer effects, with two main hypotheses. First, GLP-1 drugs may indirectly reduce cancer risk by promoting weight loss and improving metabolic health, both of which are independently associated with lower cancer incidence. Second, receptors for GLP-1—the hormone these drugs mimic—are found on the surface of some tumor cells, suggesting the drugs might directly act on the cancer's biological processes itself. Whichever mechanism is ultimately proven correct holds significant implications for the long-term medical and commercial value of these drugs.
Limitations of Observational Studies Cannot Be Ignored; Confirmation Still Requires Randomized Trials
Despite consistent data signals, researchers remain cautious about the limitations of the existing studies. All four studies rely on retrospective insurance claims records and medical databases, carrying inherent risk of bias. Patients prescribed GLP-1 drugs often have better access to healthcare resources and more stable follow-up records. These factors themselves could independently improve treatment outcomes, making it difficult to isolate the drug's effect. To confirm whether GLP-1 drugs themselves drive the observed benefits, validation through randomized controlled trials is necessary—a study design that strictly controls for differences in income level, baseline health status, and access to medical resources. Currently, neither Novo Nordisk A/S nor Eli Lilly has launched dedicated studies for cancer indications. Nonetheless, Dr. Jaroslaw Maciejewski, Vice Chair of the Cleveland Clinic Cancer Institute and lead researcher on the related study, stated that the consistent data across hundreds of thousands of patients is "hard to ignore."
Comments